Early symptoms like fatigue, breathlessness, swelling mimic common heart issues, causing cardiac amyloidosis to go undetected ...

A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose ...

An anti-hazing network honors a UVA leader, the American Heart Association lauds UVA Health for heart and stroke care, and more.

CRD-750 is the first clinical-stage PDE9 inhibitor to be evaluated in patients in both types of chronic heart failure The CYCLE-1-REF trial is evaluating patients with heart failure with reduced ...

Assessment of left ventricular systolic function is essential for diagnosing and managing cardiac diseases and provides important prognostic information to the treating clinician. However, traditional ...

A post hoc analysis of the SUMMIT trial, published in JACC, reveals that baseline body mass index (BMI) and fat distribution ...

According to expert presenters at the American Society of Preventive Cardiology’s 2025 Congress on Cardiovascular Disease Prevention, recent studies have shown significant benefit to GLP-1 inhibitors ...

Ultromics has raised $55 million in venture capital funding to expand the reach of its artificial-intelligence-powered ...

Rayan Salih, MD, a third-year internal medicine resident with the Northeast Georgia Health System, who hopes to specialize in cardiology, presented the poster, “Double Trouble: Pregnancy Challenges in ...

Dapagliflozin-spironolactone reduces NT-proBNP levels and blood pressure more than dapagliflozin alone but at the cost of a ...

Background Heart failure (HF) imposes a major health burden on women. While traditional (well-established) risk factors are ...

Glucagon-like peptide-1 (GLP-1) inhibitors have proven effective in preventing cardiovascular events, leading to experts ...